Form 4: DENTSPLY SIRONA CEO Awarded Significant Equity Compensation

DENTSPLY SIRONA's President and CEO, Daniel T. Scavilla, received substantial equity awards, including Restricted Stock Units and stock options, vesting over three years.

Summary

• Daniel T. Scavilla, President, CEO, and Director of DENTSPLY SIRONA Inc. (XRAY), was granted equity awards on March 4, 2026.
• The awards include 145,089 Restricted Stock Units (RSUs) at a price of $0, which vest in annual one-third increments over a three-year period ending March 4, 2029.
• Following this transaction, Mr. Scavilla beneficially owns 161,839.066 shares of Common Stock.
• Additionally, Mr. Scavilla was granted 2,066,600 stock options with an exercise price of $15.46, which is 115% of the closing price of the Issuer's common stock on the grant date.
• These stock options also vest in annual one-third increments over a three-year period ending March 4, 2029, and have an expiration date of March 4, 2036.
• After this transaction, Mr. Scavilla beneficially owns 2,066,600 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies strong alignment between the CEO's financial interests and the long-term performance of DENTSPLY SIRONA, which is generally favorable for shareholders.

Positives

• The significant equity award aligns the interests of the CEO, Daniel T. Scavilla, with those of long-term shareholders, incentivizing sustained company performance.
• The multi-year vesting schedule for both RSUs and stock options promotes long-term commitment and retention of key leadership.

Future Outlook

The equity awards, with their three-year vesting schedule ending March 4, 2029, indicate a long-term commitment from the CEO to the company's performance and strategic direction. The stock options, exercisable at 115% of the grant date's closing price, suggest an expectation of future share price appreciation.

Industry Context

StockSavvy.ai notes that significant equity awards to top executives like Daniel T. Scavilla are a common practice across industries, particularly in healthcare and dental technology sectors, to align leadership incentives with shareholder value creation. This type of compensation structure is designed to retain talent and motivate long-term strategic execution, a critical factor in competitive markets where innovation and market share are paramount.

Comparison to Industry Standards

• Executive equity compensation packages, including a mix of RSUs and stock options with multi-year vesting, are standard practice for CEOs of publicly traded companies comparable to DENTSPLY SIRONA Inc. in the medical device and dental technology sectors.
• The grant of stock options with an exercise price above the market price (115% of closing price) is a performance-based incentive, similar to practices seen at companies like Align Technology (ALGN) or Zimmer Biomet (ZBH), which aim to reward executives only if the stock price appreciates significantly.
• The total value of the award, while substantial, is within the expected range for a CEO of a company with DENTSPLY SIRONA's market capitalization and industry standing, reflecting competitive executive compensation benchmarks.

Stakeholder Impact

• Shareholders: The equity awards align the CEO's incentives with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: Executive compensation practices can influence overall company morale and compensation philosophy, though direct impact on general employees is not detailed.
• Creditors: No direct impact on creditors is indicated by this compensation filing.

Next Steps

• The RSUs and stock options will vest in annual one-third increments over the next three years, with the final vesting on March 4, 2029.
• The stock options will become exercisable as they vest and will expire on March 4, 2036.

Key Dates

Recommendation

This Form 4 filing reports a routine, albeit significant, equity compensation award to the CEO. While it signals management's long-term commitment and aligns their interests with shareholders, it does not provide new operational or financial performance data that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while monitoring future company performance and broader market conditions.

Keywords

DENTSPLY SIRONA, XRAY, SEC Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Executive Compensation, Daniel T. Scavilla